Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients’ treatment preferences and the imp...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds, Ioannis Tomazos, Yan Wang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Becaris Publishing Limited 2023-07-01
Saila:	Journal of Comparative Effectiveness Research
Gaiak:	ahus atypical hemolytic uremic syndrome caregiver preference eculizumab patient-reported outcomes patient preference quality of life ravulizumab treatment preference
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!